House Republicans Name for Greater Transparency of CMS National Coverage Determinations Following GAO Report

WASHINGTON, D.C. – Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, and Congressman Jason Smith (MO-08), Chairman of the House Committee on Ways and Means, issued the next joint assertion in response to a newly launched Government Accountability Office (GAO) report. The report articulates the necessity for higher transparency and reporting measures as a way to enhance the Centers for Medicare & Medicaid’s (CMS) National Coverage Determination (NCD) course of for the roughly 68 million beneficiaries underneath its purview.

“The GAO report makes clear that CMS must do more to provide transparency and accountability in its coverage decisions. Seniors should never be left waiting without clear answers about whether Medicare will cover the treatments and services their doctors recommend,” mentioned Chairmen Guthrie and Smith. “Such clarity would also inspire confidence in American innovators to develop the next treatments and cures for patients. Greater openness in the National Coverage Determination process is essential to ensure trust, timely access to care, and confidence that decisions are being made fairly and consistently. We will continue exercising oversight to make sure CMS meets its responsibility to the more than 68 million Americans who rely on Medicare.” 

Background: 

In its report, GAO discovered that whereas CMS usually meets its specified time frames for the protection determinations it considers, in instances the place determinations aren’t but thought of, there may be little to no rationalization or specified timeline for when CMS will finally make a dedication. This implies that seniors and their well being care suppliers and innovators are sometimes left in the dead of night as as to whether a selected treatment or service is roofed by Medicare, which can drive sufferers to delay remedy till a protection determination is granted by CMS.

In a latest instance, the Biden-Harris Administration’s CMS used a blanket NCD to limit Medicare protection for a complete class of Alzheimer’s therapies regardless of Food and Drug Administration approval for a similar class of drug. The opaque nature of CMS’s present dedication course of leaves beneficiaries ready, in some instances years, for entry to a remedy or service their physician has already deemed medically mandatory.

Highlights from the GAO Report: 

• CMS has not recognized or assessed the causes of delays in protection determinations.
• Some protection analyses exceeded timelines by as a lot as 351 days, together with critiques of a most cancers cell remedy and medical tools for ache administration.
• CMS officers acknowledged they don’t at the moment doc evaluation delays.

The GAO report follows a 2023 letter submitted by the Energy and Commerce and Ways and Means Committees to the Biden-Harris Administration’s Health and Human Services Secretary and CMS Administrator, highlighting grave issues with CMS’s protection course of and the necessity for timelier updates. 

###